KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Common Equity: 2009-2025

Historic Common Equity for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to $917.3 million.

  • Acadia Pharmaceuticals' Common Equity rose 58.92% to $917.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $917.3 million, marking a year-over-year increase of 58.92%. This contributed to the annual value of $732.8 million for FY2024, which is 69.72% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Common Equity stood at $917.3 million for Q3 2025, which was up 11.54% from $822.4 million recorded in Q2 2025.
  • Over the past 5 years, Acadia Pharmaceuticals' Common Equity peaked at $917.3 million during Q3 2025, and registered a low of $362.2 million during Q3 2023.
  • Its 3-year average for Common Equity is $578.1 million, with a median of $516.7 million in 2024.
  • Its Common Equity has fluctuated over the past 5 years, first fell by 25.97% in 2022, then surged by 69.72% in 2024.
  • Acadia Pharmaceuticals' Common Equity (Quarterly) stood at $540.9 million in 2021, then dropped by 25.97% to $400.4 million in 2022, then grew by 7.83% to $431.8 million in 2023, then surged by 69.72% to $732.8 million in 2024, then spiked by 58.92% to $917.3 million in 2025.
  • Its Common Equity was $917.3 million in Q3 2025, compared to $822.4 million in Q2 2025 and $765.2 million in Q1 2025.